ATC Group: J06BC04 Obiltoxaximab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J06BC04 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J06 Immune sera and immunoglobulins
3 J06B Immunoglobulins
4 J06BC Antibacterial monoclonal antibodies
5 J06BC04

Active ingredients in J06BC04

Active Ingredient

Obiltoxaximab is a monoclonal antibody that binds the protective antigen (PA) of B. anthracis. Obiltoxaximab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and oedema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin.

Related product monographs

Document Type Information Source  
 NYXTHRACIS Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

Italy (IT)

Lithuania (LT)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.